drugset / Trial / NCT00832481

Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions

NCT00832481

Unknown 60 enrolled Chinese PLA General Hospital
RandomizedParallel-groupOpen-label

Summary

This is a 17 week, randomized, single center, open-label, parallel-group study to compare glucose excursions and other efficacy and safety parameters of repaglinide thrice daily or metformin thrice daily in newly diagnosed type 2 diabetes subjects in China.

Timeline

Start
2009-01
Primary completion
2009-10
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 0.5 g
Comparator Repaglinide Small molecule 0.5 mg
Comparator Repaglinide Small molecule 1 mg
Comparator Repaglinide Small molecule 2 mg